| 辅导对象 | 蓝箭航天空间科技股份有限公司 | | | | --- | --- | --- | --- | | 成立日期 | 2015年6月1日 | | | | 注册资本 | 36,000 万元 | 法定代表人 | 联盟试 | | 京景电视 | 北京市北京经济技术开发区荣华南路 13 号院 9 号楼 1 层 101 | | | | 控股股东及 持股比例 | 伙),占公司 14.68%的股份 | 公司控股股东为张昌武及其控制的准安天绘科技信息咨询中心(有限合 | | | 行业分类 | C37 铁路、船舶、航空航天 | 在其他交易场 所(申请)挂 | 无 | | | 和其他运输设备制造业 | 牌或上市的情 | | | | 兄 | | | | 各注 | 元 | | | | 辅导协议签署时间 | 2025年7月25日 | | --- | --- | | 辅导机构 | 中国国际金融股份有限公司 | | 律师事务所 | 上海御星教授状錄在與 | | 会计师事务所 | 立信会计师事务所(特殊普通合伙) | 一位航空航天领域的从业人士表示，该公司自主研制的可重复使用液氧甲烷运载火箭，是我国首款不锈 钢液体运载火箭'朱雀三 ...

中国经济网北京7月31日讯 科兴制药（688136.SH）昨晚发布股东询价转让计划书。 2020年12月14日，科兴制药在上交所科创板上市，发行股票数量为4967.53万股，发行价格为22.33元/ 股，保荐机构（主承销商）为中信建投证券，保荐代表人为徐新岳、张星明。 科兴制药首次公开发行股票募集资金总额为11.09亿元，实际募集资金净额为9.95亿元。科兴制药实际募 资净额比原拟募资额少7.10亿元。科兴制药于2020年12月7日披露的招股说明书显示，该公司原拟募资 17.05亿元，拟分别用于药物生产基地改扩建项目、研发中心升级建设项目、信息管理系统升级建设项 目和补充流动资金。 科兴制药首次公开发行股票的发行费用（含税）总额为1.15亿元，其中，保荐及承销费用9385.58万元。 天眼查APP显示，科兴生物制药股份有限公司(曾用名：山东科兴生物制品有限公司)，成立于1997年， 位于山东省济南市，是一家以从事医药制造业为主的企业。企业注册资本19964.225万人民币。 本次拟参与科兴制药首发前股东询价转让（以下简称"本次询价转让"）的股东为深圳科益医药控股有限 公司。出让方拟转让股份的总数为6,037, ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-054 科兴生物制药股份有限公司 ? 本次询价转让为非公开转让，不通过集中竞价交易方式或大宗交易方式 进行，不属于通过二级市场减持。受让方通过询价转让受让的股份，在受让后 6 个月内不得转让； ? 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中国国际金融股份有限公司（以下简称"中金公司"）组织实施 本次询价转让。截至 2025 年 7 月 30 日，出让方所持公司股份数量、占总股本比 例情况如下： 序号 股东姓名 持股数量（股） 持股比例 （二）关于出让方是否为公司控股股东、实际控制人、持股 5%以上的股东、 董事、监事及高级管理人员 本次询价转让出让方科益医药持有公司股份比例超过 5%，为公司控股股东。 科益医药为公司实际控制人、董事长邓学勤控制的企业。 股东深圳科益医药控股有限公司（以下简称"科益医药"或"出让方"）保 证向科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）提供的信 息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 ...

Core Viewpoint - The share transfer by major shareholders of Derma Technology Group Co., Ltd. involves a total of 7,788,393 shares at a price of 18.29 CNY per share, resulting in a decrease in their combined shareholding from 40.23% to 37.28% [1][2][3] Group 1: Share Transfer Details - The share transfer price is set at 18.29 CNY per share, with a total of 7,788,393 shares being transferred [1] - After the transfer, the shareholding of Derma Investment decreases from 34.77% to 32.45%, while Creative Investment drops from 3.04% to 2.59%, and Huzhou Ligao from 2.42% to 2.24% [2] - The total shareholding of the transferring parties (Derma Investment, Creative Investment, and Huzhou Ligao) decreases from 40.23% to 37.28% [2] Group 2: Shareholder Information - Derma Investment is the controlling shareholder of the company, controlled by the actual controller Zhuo Xu, and is in concert with Creative Investment and Huzhou Ligao, collectively holding over 5% of the company's shares [2][3] - The actual controller Zhuo Xu holds 1.92% of Huzhou Ligao and serves as its executive director, indicating a unified action relationship among the transferring parties [4] Group 3: Transfer Process - The transfer process involved a price determination based on the average trading price of the company's shares over the previous 20 trading days, ensuring the price was not lower than 70% of that average [6] - A total of 100 institutional investors were invited to participate in the transfer, with 21 valid bids received, and 14 investors ultimately allocated shares [6] Group 4: Regulatory Compliance - The transfer process was reviewed by China International Capital Corporation, which confirmed that it adhered to fair and just principles and complied with relevant laws and regulations [6]

证券代码：000031 证券简称：大悦城 公告编号：2025-041 大悦城控股集团股份有限公司第十一届董事会公告 大悦城控股集团股份有限公司 发行股份购买资产并募集配套资金暨关联交易之部分限售股份 上市流通的提示性公告 五、独立财务顾问核查意见 经核查，独立财务顾问中国国际金融股份有限公司及中信证券股份有限公司 认为：本次限售股份解除限售数量、上市流通时间符合有关法律、行政法规、部 大悦城控股集团股份有限公司第十一届董事会公告 ? 本次限售股上市流通日期为2025年8月4日。 一、本次解除限售股份取得的基本情况 经中国证券监督管理委员会《关于核准中粮地产（集团）股份有限公司向 Vibrant Oak Limited（明毅有限公司，以下简称明毅）发行股份购买资产并募集 配套资金的批复》（证监许可[2018]2154 号）核准，大悦城控股集团股份有限公 司（原中粮地产（集团）股份有限公司，以下简称"公司"）以非公开发行方式 向特定投资者发行股份募集配套资金，本次募集配套资金总额为 公司（以下简称"太平人寿"）发行股份数量为 283,417,532 股。公司总股本由 具日，公司总股本未发生变化。 在深圳证券交易所 ...

Group 1 - The stock of Sely Medical increased by 10.01% and reached the trading leaderboard on July 17, with a turnover rate of 20% and notable selling by well-known speculators [1] - The top five buying firms collectively purchased 136 million yuan, while the top five selling firms sold 141 million yuan, resulting in a net outflow of 4.87 million yuan [1] - The largest buying firms included Guotai Junan Securities Headquarters, Huayin Securities Beijing Branch, and UBS Shanghai Pudong New District, with purchases of 35.27 million yuan, 29.07 million yuan, and 28.85 million yuan respectively [2] Group 2 - The largest selling firms were Guotai Junan Securities Headquarters, CITIC Securities Shanghai Branch, and GF Securities Zhengzhou Agricultural Road, with sales of 47.36 million yuan, 29.88 million yuan, and 22.20 million yuan respectively [2] - The trading activity indicates significant interest and volatility in Sely Medical's stock, as evidenced by the high turnover and the involvement of major securities firms [1][2]

Core Viewpoint - The announcement of a share reduction plan by AsiaInfo Security (688225.SH) indicates a strategic move by its shareholders to liquidate a portion of their holdings, which may impact the stock's market performance and investor sentiment [1][4]. Shareholder Reduction Plan - The shareholders, including Nanjing AsiaInfo Lexin and others, collectively hold 18,064,511 shares, representing 4.52% of the total share capital [2][3]. - The planned reduction involves selling up to 12,000,300 shares, which is 3% of the total share capital, with a breakdown of 4,000,100 shares through centralized bidding and 8,000,200 shares through block trading [3]. - The reduction period is set for three months starting 15 trading days after the announcement, with adjustments possible if corporate actions like dividends or stock splits occur [3]. Company Performance - AsiaInfo Security reported a revenue of 3.595 billion yuan for 2024, marking a year-on-year increase of 123.56%, and a net profit attributable to shareholders of 9.5906 million yuan, a significant recovery from a loss of 291 million yuan in the previous year [6]. - In Q1 2025, the company achieved a revenue of 1.290 billion yuan, a staggering growth of 347.54%, although it still reported a net loss of 227 million yuan [6][7]. - The company raised a total of 1.221 billion yuan during its IPO, with net proceeds of 1.123 billion yuan, which were intended for various security-related projects [5].

Group 1 - The stock of Zengsheng Technology experienced a decline of 10.07% on July 11, with a deviation of 7% from the daily average, indicating significant selling pressure from well-known speculators [1] - The top five buying institutions collectively purchased shares worth 55.87 million yuan, while the top five selling institutions sold shares worth 69.62 million yuan, resulting in a net outflow of 13.75 million yuan [1] - Notable buying institutions included Guotai Junan Securities Headquarters, which bought 16.05 million yuan, China Galaxy Securities Beijing Academy South Road Securities Office with 13.60 million yuan, and CITIC Securities Zhejiang Branch with 9.69 million yuan [1] Group 2 - The largest selling institution was Guotai Junan Securities Headquarters, which sold shares worth 24.83 million yuan, followed by Oriental Fortune Securities Lhasa East Ring Road Second Securities Office with 13.65 million yuan, and Ping An Securities Shenzhen Shennan Avenue Securities Office with 11.20 million yuan [2] - Other significant selling institutions included China International Capital Corporation Beijing Jianguomen Outer Street Securities Office with 10.26 million yuan and Dongxing Securities Nanjing Lushan Road Securities Office with 9.68 million yuan [2]

Core Viewpoint - Changxin Technology Group has initiated its IPO journey with a market valuation of 150.8 billion yuan, amidst challenges in the global memory chip market driven by the AI wave [2][5]. Group 1: Company Overview - Changxin Technology Group's IPO application has been accepted by the China Securities Regulatory Commission [2]. - The company has achieved a market valuation of 150.8 billion yuan following a key financing round completed in March 2024 [2]. - The company's unique "no controlling shareholder" structure is highlighted, with the largest shareholder holding 21.67% [2][3]. Group 2: Shareholder Structure - The largest shareholder, Hefei Qinghui Electric Enterprise Management Partnership, is ultimately funded by Hefei Industrial Investment Holding Group, a key player in the "Hefei Model" of local government investment [3]. - The "Hefei Model" involves significant long-term investments in strategic emerging industries, with previous successes in sectors like new displays and electric vehicles [3]. Group 3: Strategic Partnerships - Changxin Group has formed a strong partnership with leading domestic MCU company, Zhaoyi Innovation, which has invested 1.5 billion yuan in the company [4]. - Zhaoyi Innovation not only acts as a shareholder but also as a crucial customer, with projected purchases from Changxin Group reaching 1.61 billion yuan in 2025 [4]. Group 4: Market Challenges - The global DRAM market is experiencing a structural divide, with high demand for high-end products driven by AI, while traditional markets are recovering slowly [5][6]. - Changxin Group's current product offerings are primarily in the slower-recovering general DRAM market, which is closely tied to the performance of traditional consumer electronics [5][6]. - The company faces significant technological gaps in the high-margin HBM sector compared to international giants like Samsung and SK Hynix, posing a challenge for future growth [6]. Group 5: Market Position and Future Outlook - Changxin Group's successful IPO would fill a critical gap in the A-share semiconductor sector, as it is currently the only DRAM integrated device manufacturer of its scale [6]. - The company's ability to navigate its capital market journey will test its technological advancement capabilities and the market's long-term valuation of Chinese core technology assets [6].

Core Viewpoint - Chengdu Xian Dao (688222.SH) announced the termination of a major asset restructuring plan due to the inability to reach consensus on key terms with the transaction parties, which included transaction scheme, pricing, and performance commitments [1][2]. Group 1: Termination of Major Asset Restructuring - The company disclosed that it had been actively organizing the transaction since establishing the intent with the counterparties, but failed to agree on core terms [2]. - The decision to terminate the transaction was made to protect the interests of the company and all shareholders after thorough consideration and friendly negotiations with the counterparties [2]. Group 2: Company Background and Financials - Chengdu Xian Dao was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 16, 2020, with an issuance of 40.68 million shares at a price of 20.52 yuan per share [2]. - The total funds raised from the initial public offering amounted to 834.75 million yuan, with a net amount of 746.01 million yuan after deducting issuance costs, exceeding the original plan by 85.98 million yuan [2]. - The funds were intended for projects related to new molecular design and drug research center construction [2]. Group 3: Shareholding Structure - The controlling shareholder and actual controller of the company is Jin Li, who holds British nationality [3].